A single-dose, randomized, two-period, two-sequence, crossover pilot bioequivalence study on formulations containing rivaroxaban and acetylsalicylic acid in healthy volunteers under fasting conditions.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509841-12-00

Acronym

01/2023/Pozlab

Enrollment

Registered

2024-02-05

Start date

2024-02-28

Completion date

2024-03-18

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

increased blood clotting

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Czechia

None listed

Source: EU CTIS · Data processed: Feb 4, 2026